CMV and blood transfusions

Reviews in Medical Virology

Volumn 12, Issue 4, 2002, Pages 211-219

  Roback, John D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; BLOOD COMPONENT THERAPY; BLOOD DONOR; BLOOD TRANSFUSION; CHILD; CYTOMEGALOVIRUS INFECTION; HERPES VIRUS; HUMAN; INFECTION RISK; REVIEW; VIRUS INFECTION; VIRUS TRANSMISSION;

ADULT; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISINFECTION; DNA, VIRAL; FEMALE; HUMANS; INFANT, NEWBORN; POLYMERASE CHAIN REACTION; PREGNANCY; RISK FACTORS;

EID: 0036322606     PISSN: 10529276     EISSN: None     Source Type: Journal    
DOI: 10.1002/rmv.353     Document Type: Review

References (88)

1. A syndrome following total body perfusion
2. A syndrome resembling infectious mononucleosis after open-heart surgery
3. Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis
4. Rise of cytomegalovirus antibodies in an infectious-mononucleosis-like syndrome after transfusion
5. Cytomegalovirus mononucleosis with jaundice as presenting sign
6. Transfusion transmission of cytomegalovirus confirmed by restriction endonuclease analysis
7. Blood donations and viruses
8. Detection of human herpesvirus 8 DNA sequences in tissues and bodily fluids
9. Cytomegalovirus: Genetic variation of viral genomes
10. Transfusion-associated cytomegalovirus infections
11. Asymptomatic cytomegalovirus infection following blood transfusion in tumor surgery
12. Transfusion-associated cytomegalovirus infections in seropositive cardiac surgery patients
13. Cytomegalovirus infections in seropositive patients after transfusion. The effect of red cell storage and volume
14. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants
15. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation
16. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant
17. Prevention of cytomegalovirus infection following bone marrow transplantation: A randomized trial of blood product screening
18. The risk of cytomegalovirus infection in solid organ and bone marrow transplant recipients: Transfusion of blood products
19. Transfusion of the HIV seropositive patient: Immunomodulation, viral reactivation, and limiting exposure to EBV (HHV-4), CMV (HHV-5) and HHV-6, 7, and 8
20. Indications for the use of cytomegalovirus-seronegative blood products
21. The risk of transmitting cytomegalovirus to patients receiving blood transfusions
22. The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression
23. Transfusion-and community-acquired cytomegalovirus infection in children with malignant disease: A prospective study
24. Human cytomegalovirus replicates in primary human bone marrow cells
25. Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrow
26. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors
27. Human cytomegalovirus suppression of and latency in early hematopoietic progenitor cells
28. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells
29. Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome
30. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors
31. Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines
32. Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages
33. Human cytomegalovirus productively infects primary differentiated macrophages
34. Cytomegalovirus infections associated with leukocyte transfusions
35. The effect of granulocyte transfusions on the incidence of cytomegalovirus infection after allogeneic marrow transplantation
36. Risk factors for cytomegalovirus infection after human marrow transplantation
37. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant
38. Methods for the reduction of transfusion-transmitted cytomegalovirus infection: Filtration versus the use of seronegative donor units
39. The risk of transmitting cytomegalovirus infection by fresh frozen plasma
40. Latent cytomegalovirus infection in blood donors
41. Latent infection and the elusive cytomegalovirus
42. CMV DNA in plasma of seroconverting and anti-CMV seroprevalent blood donors
43. Quantitative analysis of latent human cytomegalovirus
44. Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors
45. Longitudinal monitoring of WBC subsets in packed RBC units after filtration: Implications for transfusion transmission of infections
46. Cytomegalovirus (CMV) DNA is detected infrequently in healthy US blood donors: Results of a multicenter trial
47. The effect of leukocyte-reduction method on the amount of human cytomegalovirus in blood products: A comparison of apheresis and filtration methods
48. Epidemiology of cytomegalovirus infections
49. Reducing the risk for transfusion-transmitted cytomegalovirus infection
50. Transfusion-acquired cytomegalovirus infection in children in a hyperendemic area
51. Survival of cytomegalovirus in viremic blood under blood bank storage conditions
52. Posttransfusion cytomegalovirus infections
53. A serologic study of cytomegalovirus infections associated with blood transfusions
54. Cytomegalovirus-seronegative blood components for the prevention of primary cytomegalovirus infection after marrow transplantation. Considerations for blood banks
55. Comparison of five methods of cytomegalovirus antibody screening of blood donors
56. Detection of cytomegalovirus antibody with latex agglutination
57. Comparison of a latex agglutination test with five other methods for determining the presence of antibody against cytomegalovirus
58. Comparison of six methods for the detection of antibody to cytomegalovirus
59. Comparison of three methods for detecting antibody to cytomegalovirus
60. Discordant cellular and humoral immune responses to cytomegalovirus infection in healthy blood donors: Existence of a Th1-type dominant response
61. Asymptomatic primary cytomegalovirus infection: Virologic and immunologic features
62. Human cytomegalovirus in blood of immunocompetent persons during primary infection: Prognostic implications for pregnancy
63. Cytomegalovirus and Their replication
64. Cytomegalovirus
65. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytofmegalovirus infection after bone marrow transplantation
66. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes
67. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products
68. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors
69. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection
70. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection
71. Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors
72. Polymerase chain reaction for detection of human cytomegalovirus infection in a blood donor population
73. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells
74. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all sero-positive and most seronegative healthy blood donors over time
75. Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction
76. Primer-mediated enzymatic amplification of cytomegalovirus (CMV) DNA. Application to the early diagnosis of CMV infection in marrow transplant recipients
77. Rapid detection of cytomegalovirus DNA and RNA in blood of renal transplant patients by in vitro enzymatic amplification
78. Failure to detect human cytomegalovirus DNA in peripheral blood leukocytes of healthy blood donors by the polymerase chain reaction
79. Detection of cytomegalovirus in blood donors by the polymerase chain reaction
80. Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification
81. Photochemical inactivation of pathogenic bacteria in human platelet concentrates
82. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light
83. Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: Current research perspectives
84. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates
85. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA
86. Prevention of post-transfusion cytomegalovirus infection: Recommendations for clinical practice
87. Proceedings of a consensus conference: Prevention of post-transfusion CMV in the era of universal leukoreduction